US 12171765
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted A61KA61K31/502A61K31/505
Quick answer
US patent 12171765 (Combination therapies using PRMT5 inhibitors for the treatment of cancer) held by Mirati Therapeutics, Inc. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/502, A61K31/505, A61K31/506, A61K31/519